Data from the Syn-Sleep Study shows the Syn-One Test detected phosphorylated alpha-synuclein in skin biopsies of 75% of ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease ...

Researchers from Aarhus University and Synuca Therapeutics recently presented a novel drug-like small-molecule inhibitor of sarco/endoplasmic reticulum calcium ATPase (SERCA), SYN-4569, with superior ...

This has the potential to improve diagnosis and drug development for these diseases. Synucleinopathies are neurodegenerative diseases such as Parkinson's disease and dementia with Lewy bodies. They ...

This has the potential to improve diagnosis and drug development for these diseases. Synucleinopathies are neurodegenerative diseases such as Parkinson’s disease and dementia with Lewy bodies. They ...

Amprion’s SAAmplify-ɑSYN (formerly SYNTap®) biomarker test is the only validated seed amplification assay available to help diagnose synucleinopathies associated with Parkinson’s disease ...

Aggregates of α-synuclein are the hallmark of synucleinopathies such as Parkinson’s disease and dementia with Lewy bodies, but could other protein inclusions contribute to pathology? Yes, say ...

the study's findings will greatly advance their understanding of the function of c-Abl kinase in alpha synucleinopathies. Also Read: HPCL, BPCL, IOCL gain up to 5%; Nifty Oil & Gas Index rises 1.5 ...